TREATMENT OUTCOMES OF UTERINE CARCINOMA: A SINGLE INSTITUTION RETROSPECTIVE STUDY

Abstract

BackgroundEndometrial cancer has a lifetime risk of 2.6% for women living in industrialized countries and it is the most prevalent kind of cancer diagnosed in those regions. In terms of gynecologic cancer-related deaths, it ranks after ovarian and cervical cancer as the third most common cause. ObjectivesTo evaluate endometrial cancer patients’ long-term treatment outcomes, including disease-free survival and overall survival, as well as to pinpoint independent predictive markers. Materials and MethodsAt the Zhianawa Cancer Center, a retrospective analysis was conducted. All patients who had been referred for radiation therapy between March 2009 and January 2019 were included in the research, except those who had distant metastases. In the end, 89 patients were included. Using the Kaplan-Meier technique, overall survival and disease-free survival were calculated, and the significance of the variations across curves was evaluated using the log-rank test. ResultsAll patients underwent surgery, 96.6% received adjuvant radiotherapy, and 42.7% received concomitant chemotherapy. The 5-year and 10-year disease-free survivals were 62.9% and 56.2%, and the overall 5-year and 10-year survivals were 74.2% and 66.3% respectively. The statistically significant variables impacting disease-free survival were lymphovascular invasion and marginal status, and the only statistically significant prognostic variable affecting overall survival was the FIGO stage. ConclusionIn this analysis, we concluded that uterine cancer has a good prognosis, and its outcome was influenced by stage, lymphovascular space invasion, and surgical marginal status.